Akebia Therapeutics (AKBA) Change in Receivables (2013 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Change in Receivables data on file, last reported at $15.7 million in Q1 2026.

• On a quarterly basis, Change in Receivables fell 43.66% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 94.59% decrease from a year earlier, with the FY2025 full-year figure at $14.1 million, up 449.53% from the prior year.
• Change in Receivables for Q1 2026 stood at $15.7 million, up from -$19.1 million in the prior quarter.
• Over the last five years, Change in Receivables for AKBA reached as high as $27.9 million in Q1 2025 and fell as low as -$58.7 million in Q3 2022.
• Historically, Change in Receivables has averaged $794647.1 across 5 years, with a median of $3.1 million in 2024.
• Across the five-year window, Change in Receivables jumped 7399.56% in 2022 and sank 721.28% in 2025, its largest moves.
• Year by year, Change in Receivables stood at $17.0 million in 2022, then declined by 1.86% to $16.7 million in 2023, then plunged by 81.59% to $3.1 million in 2024, then sank by 721.28% to -$19.1 million in 2025, then surged by 182.23% to $15.7 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $15.7 million in Q1 2026, -$19.1 million in Q4 2025, and -$6.2 million in Q3 2025.